UTHR Stock Analysis: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$478.27
3.27 (0.69%)
▲
5d:
+0.31%
30d:
-3.71%
90d:
+7.37%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Feb 25, 2026
21d
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called UTHR this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UTHR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: UTHR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$615.11
Based on 5.0% avg growth
INTRINSIC VALUE TODAY
$381.93
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $478.27, which is considered fair relative to its 30-day fair value range of $468.55 to $494.45. The stock's valuation (Forward PE: 16.7) is in line with its historical norms (16.9). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This pessimistic expectation contrasts with the company's recent 12.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, UTHR is in a strong uptrend. The price is approaching resistance at $479.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UTHR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $530.84 (+11.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UTHR is in a strong uptrend. The price is approaching resistance at $479.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UTHR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $530.84 (+11.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$468.55 -
$494.45
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.7%
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($530.84)
Fair Price Analysis
30-Day Fair Range
$468.55 -
$494.45
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$29.14
(6.1%)
Support & Resistance Levels
Support Level
$462.02
Resistance Level
$479.41
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
16.73
Wall Street Target
$530.84
(+11.0%)
Revenue Growth (YoY)
6.8%
Earnings Growth (YoY)
12.1%
Profit Margin
40.6%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
16.7 vs 16.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$476.84
(0%)
2-Year Target
$475.40
(-1%)
3-Year Target
$473.98
(-1%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
$478.82
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 5.9%)
$756.70
(+58%)
Base:
(SPY PE: 16.7, Growth: 5.9%)
$567.67
(+19%)
Bear:
(PE: 14.2, Growth: 5.9%)
$482.52
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 17.73 | Current EPS (TTM): $26.48
Bull Case
$557.57
(+17%)
Analyst growth 8.0%, PE expands to 19.5
Base Case
$506.88
(+7%)
Market implied 8.0%, PE stable at 17.7
Bear Case
$319.25
(-33%)
Severe decline -20.0%, PE contracts to 15.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.7 to 16.9
Stabilization Target:
$483.15
(+1.0%)
PE Expansion Potential:
+1.0%
Last updated: February 03, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Martine A Rothblatt
SELL
4000 shares
2025-10-22
Martine A Rothblatt
SELL
4000 shares
2025-10-20
Michael Benkowitz
SELL
22500 shares
2025-10-20
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$37 | 59 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
